Please login to the form below

Not currently logged in
Email:
Password:

Sanofi in TB partnership with Cornell

Sanofi is to enter a research collaboration with Weill Cornell Medical College to identify new anti-infective treatments for the treatment of tuberculosis

Sanofi is to enter a research collaboration with Weill Cornell Medical College to identify new anti-infective treatments for the treatment of tuberculosis (TB).

Research will be focused on drugs that shorten the current course of TB treatment and have the potential to provide effective treatment against strains of TB that are resistant or susceptible to current therapies.

Sanofi will provide 80,000 chemical compounds to Dr Carl Nathan's laboratory at Weill Cornell, the medical college of New York's Cornell University.

The compounds will be screened to assess their ability to inhibit growth of Mycobacterium tuberculosis, the bacterium that causes most cases of TB.

Funding for the screening is provided by the Bill & Melinda Gates Foundation.

"This research collaboration with Weill Cornell will enable us to explore the potential of our existing compound library and pool the extensive knowledge of Dr Nathan and his colleagues," said Elias Zerhouni, president, global R&D at Sanofi. "Should a compound be identified through this collaboration, with Sanofi's drug development expertise, we hope to benefit TB patients worldwide in continuation of our long standing commitment to global health."

30th June 2011

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN LEC

Welcome to our world. We specialise in creating, launching and revitalising brands all over the world. We blend science, creative,...

Latest intelligence

Free White Paper: Customer Experience for Pharma
To learn why an effective customer experience strategy is vital for pharma, download our white paper “Customer experience for pharma” to learn more....
How ethical is your brand plan? Introducing the hEQ.
Assess your brand plan’s Healthcare Ethics Quotient and see how these questions can give your brand plan a new perspective and engage your internal teams and external customers....
solution_options.png
Why e-detailing must give options to healthcare professionals
We know, we know. You want to talk about your treatment right away, but this really is an essential step that will make your e-detailing even more credible....